BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma-Reference-Cited by-同舟云学术

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Published:2015-09 Issue:9 Volume:15 Page:531-535
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Veeraputhiran Muthu,Jain Tania,Deol Abhinav,Ayash Lois,Kim Seongho,Dyson Gregory,Bhutani Divaya,Lum Lawrence G.,Ratanatharathorn Voravit,Uberti Joseph P.,Abidi Muneer H.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321;Barlogie;J Clin Oncol,2006

2. High-dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution;Blade;Bone Marrow Transplant,2000

3. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

4. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry;Cook;Biol Blood Marrow Transplant,2011

5. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy;Tricot;Bone Marrow Transplant,1995

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations;Transplantation and Cellular Therapy;2023-11

2. Clinical analysis of bacterial infection characteristics in lymphoma patients with high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation-a single-centered retrospective study;Combinatorial Chemistry & High Throughput Screening;2023-09-15

3. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

4. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m² versus 200mg/m² preparative regimens in patients with multiple myeloma;Leukemia & Lymphoma;2023-05-18

5. First-line treatment of multiple myeloma in both transplant and non-transplant candidates;Expert Review of Anticancer Therapy;2023-05-16